The immune checkpoint inhibitors atezolizumab and pembrolizumab, both PD-1/PD-L1 axis inhibitors, have been recently approved by the FDA for the treatment of unresectable, locally advanced or metastatic TN breast cancer [111,112]. This evidence concerns the gene CD274 and breast carcinoma.